

chain nodes :
6 25 32 33 34 35 36 37 38 39 40 41
ring nodes :
1 2 3 4 5 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
26 27 28 29 30 31
chain bonds :
1-6 2-13 3-19 6-7 9-33 11-34 24-25 25-26 25-32 31-38 33-39 33-40 33-41
34-35 34-36 34-37
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28
28-29 29-30
30-31
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5 25-32
exact bonds :
2-13 3-19 6-7 9-33 11-34 24-25 25-26 31-38 33-39 33-40 33-41 34-35 34-
36
34-37
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20
19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28 28-29 29-30 30-31

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:23:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 80 TO 560
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:23:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 379 TO ITERATE

100.0% PROCESSED 379 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=> fil reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.55 172.76

FILE 'REGISTRY' ENTERED AT 13:24:19 ON 27 SEP 2007

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2007 HIGHEST RN 948239-70-1
DICTIONARY FILE UPDATES: 26 SEP 2007 HIGHEST RN 948239-70-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l3
SAMPLE SEARCH INITIATED 13:24:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 80 TO 560
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L1

=> fil reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.45 173.21

FILE 'REGISTRY' ENTERED AT 13:24:29 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 SEP 2007 HIGHEST RN 948239-70-1
DICTIONARY FILE UPDATES: 26 SEP 2007 HIGHEST RN 948239-70-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l3

SAMPLE SEARCH INITIATED 13:24:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 80 TO 560
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10574712.str



chain nodes :
6 25 32 33 34 35 36 37 38 39 40 41
ring nodes :
1 2 3 4 5 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 26 27 28 29 30 31
chain bonds :
1-6 2-13 3-19 6-7 9-33 11-34 24-25 25-26 25-32 31-38 33-39 33-40 33-41 34-35 34-36 34-37
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15

15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28
28-29 29-30
30-31
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5 25-32
exact bonds :
2-13 3-19 6-7 9-33 11-34 24-25 25-26 31-38 33-39 33-40 33-41 34-35 34-
36
34-37
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20
19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28 28-29 29-30 30-31

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:CLASS

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l6
SAMPLE SEARCH INITIATED 13:25:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 80 TO 560
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s l6 full
FULL SEARCH INITIATED 13:25:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 379 TO ITERATE

100.0% PROCESSED 379 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L8 3 SEA SSS FUL L6

=> d scan

L8 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (9CI)
MF C28 H16 Cl F6 N5 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Methanone, [4-amino-2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (9CI)
MF C28 H17 Cl F6 N6 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(1-oxido-4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)-
MF C28 H16 Cl F6 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=>
Uploading C:\Program Files\Stnexp\Queries\10574712a.str





chain nodes :
6 25 32
ring nodes :
1 2 3 4 5 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
26 27 28 29 30 31
chain bonds :
1-6 2-13 3-19 6-7 24-25 25-26 25-32
ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28
28-29 29-30
30-31
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5 25-32
exact bonds :
2-13 3-19 6-7 24-25 25-26
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20
19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28 28-29 29-30 30-31

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:CLASS

L9   STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9   STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l9
SAMPLE SEARCH INITIATED 13:26:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1 TO ITERATE

100.0% PROCESSED   1 ITERATIONS   1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 1 TO   80
PROJECTED ANSWERS: 1 TO   80

L10   1 SEA SSS SAM L9

=> s l9 full
FULL SEARCH INITIATED 13:26:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   33 TO ITERATE

100.0% PROCESSED   33 ITERATIONS   18 ANSWERS
SEARCH TIME: 00.00.01

L11   18 SEA SSS FUL L9

=> fil capl
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   345.10   518.31

FILE 'CAPLUS' ENTERED AT 13:26:58 ON 27 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Sep 2007 VOL 147 ISS 14
FILE LAST UPDATED: 26 Sep 2007 (20070926/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l11
L12 3 L11

=> d l12 ibib hitstr abs 1-3

L12 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:792802 CAPLUS Full-text
DOCUMENT NUMBER: 145:217965
TITLE: Tachykinin receptor antagonists
INVENTOR(S): Kulanthaivel, Palaniappan
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 27pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006083711	A1	20060810	WO 2006-US2929	20060127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-648969P P 20050201
OTHER SOURCE(S): MARPAT 145:217965
IT 905265-27-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tachykinin receptor antagonists)
RN 905265-27-2 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(1-oxido-4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (CA INDEX NAME)



IT 622370-35-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(tachykinin receptor antagonists)
RN 622370-35-8 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (9CI) (CA INDEX NAME)



GI



I

AB The present invention provides novel compds. of Formula (I), where X = -CH(OH)- or -C(O)-, compns. thereof, and methods for using the compds. in the treatment of disorders associated with an excess of tachykinins.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:409503 CAPLUS Full-text

DOCUMENT NUMBER: 142:469259

TITLE: Novel crystalline forms of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)methanone

INVENTOR(S): Timpe, Carsten; Borghese, Alfio; Coffey, David Scott; Footman, Pamela Kaye; Pedersen, Steven Wayne; Reutzel-Edens, Susan Marie; Tameze,. Shella Lenyonga; Weber, Carsten

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042515	A1	20050512	WO 2004-US30914	20041012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285855	A1	20050512	AU 2004-285855	20041012
CA 2542140	A1	20050512	CA 2004-2542140	20041012
EP 1675846	A1	20060705	EP 2004-793893	20041012

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR	2004015010	A	20061107	BR 2004-15010		20041012
CN	1863791	A	20061115	CN 2004-80029139		20041012
JP	2007509143	T	20070412	JP 2006-536635		20041012
US	2007078166	A1	20070405	US 2006-574712		20060405
MX	2006PA04444	A	20061211	MX 2006-PA4444		20060421
IN	2006KN01039	A	20070420	IN 2006-KN1039		20060424
NO	2006002371	A	20060524	NO 2006-2371		20060524
PRIORITY APPLN. INFO.:				US 2003-514300P	P	20031024
				WO 2004-US30914	W	20041012

IT 622370-35-8P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystalline forms of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-
[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)methanone)
RN 622370-35-8 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (9CI) (CA INDEX NAME)



GI



I

AB The present invention provides novel crystalline forms. of I. I was prepared, e.g., by reaction of 1-azidomethyl-3,5-bistrifluoromethylbenzene and (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl)pyridin-3-yl]methanone phosphate.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:875262 CAPLUS Full-text

DOCUMENT NUMBER: 139:364937

TITLE: Preparation of triazole derivatives as tachykinin receptor antagonists

INVENTOR(S): Amegadzie, Albert Kudzovi; Gardinier, Kevin Matthew; Hembre, Erik James; Hong, Jian Eric; Jungheim, Louis Nickolaus; Muehl, Brian Stephen; Remick, David Michael; Robertson, Michael Alan; Savin, Kenneth Allen

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091226	A1	20031106	WO 2003-US10681	20030422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483159	A1	20031106	CA 2003-2483159	20030422
AU 2003230829	A1	20031110	AU 2003-230829	20030422
BR 2003009534	A	20050201	BR 2003-9534	20030422
EP 1501809	A1	20050202	EP 2003-723929	20030422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1646502	A	20050727	CN 2003-809104	20030422
JP 2005536458	T	20051202	JP 2003-587786	20030422
TW 265807	B	20061111	TW 2003-92109375	20030422
NZ 535886	A	20070727	NZ 2003-535886	20030422
US 2005239786	A1	20051027	US 2004-512249	20041020
MX 2004PA10622	A	20050125	MX 2004-PA10622	20041026
ZA 2004008670	A	20051026	ZA 2004-8670	20041026
NO 2004005120	A	20041207	NO 2004-5120	20041124
PRIORITY APPLN.. INFO.:			US 2002-376121P P	20020426
			WO 2003-US10681 W	20030422

OTHER SOURCE(S): MARPAT 139:364937

IT 622370-35-8P 622370-61-0P 622370-62-1P
622370-63-2P 622370-64-3P 622370-65-4P
622370-66-5P 622370-67-6P 622370-75-6P
622370-76-7P 622370-79-0P 622370-80-3P
622370-81-4P 622370-82-5P 622370-90-5P
622370-91-6P 622371-37-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole derivs. as tachykinin receptor antagonists)

RN 622370-35-8 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 622370-61-0 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl]phenyl- (9CI) (CA INDEX NAME)



RN 622370-62-1 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 622370-63-2 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 622370-64-3 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl][2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 622370-65-4 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 622370-66-5 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 622370-67-6 CAPLUS
CN Methanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 622370-75-6 CAPLUS
CN Methanone, (2-chlorophenyl)[2-[5-(4-pyridinyl)-1-[[3-(trifluoromethyl)phenyl]methyl]-1H-1,2,3-triazol-4-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 622370-76-7 CAPLUS
CN Methanone, (2-chlorophenyl)[2-[1-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 622370-79-0 CAPLUS
CN Methanone, (2-chlorophenyl)[2-[1-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 622370-80-3 CAPLUS
CN Methanone, (2-chlorophenyl)[2-[5-(4-pyridinyl)-1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-1,2,3-triazol-4-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 622370-81-4 CAPLUS
CN Methanone, [2-[1-[[2,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (9CI) (CA INDEX NAME)





RN 622370-82-5 CAPLUS
CN Methanone, (2-chlorophenyl)[2-[1-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 622370-90-5 CAPLUS
CN Methanone, (2-chlorophenyl)[2-[1-[(3,5-dichlorophenyl)methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 622370-91-6 CAPLUS
CN Methanone, (2-chlorophenyl)[2-[1-[(3,5-dimethylphenyl)methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 622371-37-3 CAPLUS
CN Methanone, [4-amino-2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)- (9CI) (CA INDEX NAME)



GI



I



II

AB The title compds. [I; D = alkanediyl; R1 = (un)substituted Ph; R4 = 2-chlorobenzoyl(or benzyl) substituted (hetero)aryl, etc.; R5 = H, halo, alkyl, etc.], useful as inhibitors of the NK-1 subtype of tachykinin receptors, were prepared Thus, reacting (2-bromopyridin-3-yl)(2- chlorophenyl)methanone with 1-[3,5-bis(trifluoromethyl)benzyl]-5-methyl-4- tributylstannyl-1H-[1,2,3]triazole in the presence of PdCl2(PPh3)2 in DMF afforded 54% II. Pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.75	535.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

STN INTERNATIONAL LOGOFF AT 13:28:27 ON 27 SEP 2007